cd19/cd20/bcma car-t
Refractory
Shanghai Cell Therapy Group Co.,LtdCell therapyEarly Phase 1Active
C
38/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 81/ 100
Competitive context
20 Active assets in the Refractory cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
DEXAMETHASONE UNC Lineberger Comprehensive Cancer Center | Phase 2 | B |
Cyclophosphamide The Second Hospital of Shandong University | Phase 2 | B |
Epirubicin Memorial Sloan Kettering Cancer Center | Phase 2 | CCC |
Pembrolizumab Memorial Sloan Kettering Cancer Center | Phase 2 | CCC |
Isatuximab UNC Lineberger Comprehensive Cancer Center | Phase 2 | CCC |
View all 33 →
Same molecule, other indications
cd19/cd20/bcma car-t is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →